IRIS UniCatt

Bacigalupo, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.045
NA - Nord America 4.466
EU - Europa 3.026
SA - Sud America 1.095
AF - Africa 148
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.801
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.293
SG - Singapore 2.198
CN - Cina 1.231
BR - Brasile 864
IT - Italia 683
SE - Svezia 669
VN - Vietnam 400
FR - Francia 368
DE - Germania 336
ID - Indonesia 209
IE - Irlanda 192
IN - India 170
GB - Regno Unito 166
TR - Turchia 156
JP - Giappone 149
FI - Finlandia 118
RU - Federazione Russa 112
PL - Polonia 86
CA - Canada 83
AR - Argentina 81
HK - Hong Kong 76
UA - Ucraina 74
KR - Corea 71
IQ - Iraq 68
MX - Messico 60
BD - Bangladesh 51
NL - Olanda 45
TH - Thailandia 43
ZA - Sudafrica 39
EC - Ecuador 30
VE - Venezuela 30
ES - Italia 28
CO - Colombia 27
PH - Filippine 27
AT - Austria 26
BE - Belgio 26
MY - Malesia 24
CL - Cile 23
PK - Pakistan 21
CI - Costa d'Avorio 20
UZ - Uzbekistan 18
IR - Iran 17
AU - Australia 16
CZ - Repubblica Ceca 16
EG - Egitto 16
JO - Giordania 16
UY - Uruguay 16
SA - Arabia Saudita 15
KE - Kenya 14
MA - Marocco 14
PY - Paraguay 12
DZ - Algeria 11
CH - Svizzera 8
KZ - Kazakistan 8
NP - Nepal 8
RO - Romania 8
TN - Tunisia 8
TW - Taiwan 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
IL - Israele 7
LT - Lituania 7
OM - Oman 7
SN - Senegal 7
BO - Bolivia 6
LB - Libano 6
PT - Portogallo 6
BG - Bulgaria 5
DK - Danimarca 5
JM - Giamaica 5
KG - Kirghizistan 5
TT - Trinidad e Tobago 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
GE - Georgia 4
GR - Grecia 4
HR - Croazia 4
HU - Ungheria 4
MD - Moldavia 4
PE - Perù 4
QA - Qatar 4
AL - Albania 3
AM - Armenia 3
BA - Bosnia-Erzegovina 3
HN - Honduras 3
PA - Panama 3
PR - Porto Rico 3
RS - Serbia 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
CR - Costa Rica 2
EU - Europa 2
GT - Guatemala 2
GY - Guiana 2
LI - Liechtenstein 2
LK - Sri Lanka 2
Totale 13.770
Salva come PNG Salva come JPEG
Città #
Singapore 1.119
Chandler 555
San Jose 486
Ashburn 414
Beijing 219
Dublin 188
Jakarta 187
Hefei 182
Lauterbourg 144
Ho Chi Minh City 139
Rome 134
Tokyo 133
Los Angeles 129
Izmir 120
Ann Arbor 119
Hanoi 106
Wilmington 106
New York 100
Nanjing 98
Milan 97
Dallas 87
São Paulo 82
Warsaw 78
Frankfurt am Main 77
San Mateo 74
Moscow 71
Jacksonville 69
Munich 69
Council Bluffs 68
Seoul 67
Boston 65
Fairfield 65
Hong Kong 64
Houston 64
Chicago 59
The Dalles 57
Cattolica 56
Princeton 54
Kent 53
Nanchang 53
Hyderabad 52
Florence 50
Helsinki 46
Seattle 45
Paris 44
Bangkok 40
Dearborn 38
Marseille 37
Santa Clara 37
Lawrence 36
Redwood City 36
Boardman 33
Shanghai 33
Woodbridge 33
Fuzhou 32
Brussels 25
Buffalo 25
Nuremberg 25
Atlanta 24
Montreal 24
Guangzhou 23
Hebei 23
Bremen 22
Kunming 22
Lancaster 22
Orem 22
Redmond 22
Cambridge 21
Lappeenranta 21
Manila 21
Mexico City 21
Tianjin 21
Toronto 21
Abidjan 20
Belo Horizonte 20
Jiaxing 20
London 20
Porto Alegre 20
Shenyang 20
Hangzhou 19
Phoenix 19
Baghdad 18
Changsha 18
Brasília 17
Manchester 17
Rio de Janeiro 17
Brooklyn 16
Da Nang 16
Denver 16
Haiphong 16
Johannesburg 16
Mountain View 16
Pune 16
Dhaka 15
Kuala Selangor 15
Tashkent 15
Amman 14
Curitiba 14
San Francisco 14
Turku 14
Totale 7.562
Salva come PNG Salva come JPEG
Nome #
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 380
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies:uptade consensus recommendations of the European Society for Blood 287
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogenic stem cell transplantation: consensus-besed recommendations by an international expert panel 257
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 146
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 145
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 144
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 143
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party 140
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 136
Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. 135
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 133
Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal 131
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 127
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 127
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 126
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 124
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 123
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation 119
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 119
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 118
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 118
Severe cmv infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in a mantle cell lymphoma old patient 117
UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen 116
Unrelated cord blood transplantation and post-transplant cyclophosphamide 115
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial 114
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 113
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 113
Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management 112
THE IMPACT OF EDUCATION ON PATIENTS' PSYCHOEMOTIONAL STATUS DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTRE PROSPECTIVE STUDY BY THE GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO 112
Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review 112
Nasopharynxkarzinom in einem europäischen Gebiet mit geringer Inzidenz: Eine prospektive Beobachtungsanalyse der Kopf- und Hals-Studiengruppe der Italienischen Gesellschaft für Radioonkologie (AIRO) 112
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 112
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation 112
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 111
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? 111
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 110
A closer look at permissive HLA mismatch 110
Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party 109
ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- And Long-term Outcomes 109
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 108
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 105
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide :does graft cell content have an impact on main clinical outcomes? 105
Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups 104
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study 104
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 104
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients 102
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 102
Integrating transplantation with antibodies and genetically modified T-cell therapies 102
Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant 102
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 102
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? 101
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 100
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: A registry study by the European society for blood and marrow transplantation 100
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients 99
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 99
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? 99
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 98
Alternative donor transplants for severe aplastic anemia: current experience 97
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression 97
RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT 97
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 97
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia 95
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 95
Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? 95
Antithymocyte globulin in the conditioning regimen: why not? 95
Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation 95
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: A report from the acute leukemia working party of the EBMT 95
Unrelated cord blood transplantation and post-transplant cyclophosphamide 95
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 95
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 94
Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: A retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation 94
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 92
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 91
Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia 91
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 90
Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center 89
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 89
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 89
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 88
Post-transplant cyclophosphamide versus antithymocyte-globulin as graft versus host disease prophylaxis in haploidentical transplant 88
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 88
CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation 88
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 88
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 87
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 87
Alternative donor transplants for severe aplastic anemia: Current experience 86
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 85
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. 85
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 84
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients 84
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 83
PURLs: Light therapy for nonseasonal major depressive disorder? 83
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet 83
Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients 83
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 83
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT 82
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 81
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012 80
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 80
Second haploidentical stem cell transplantation for primary graft failure 80
Totale 10.957
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.412
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.412
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021106 0 0 0 0 0 0 0 0 0 24 65 17
2021/2022744 72 12 31 31 49 15 15 116 49 72 129 153
2022/20231.746 260 228 137 243 140 215 79 117 169 50 85 23
2023/20241.169 41 262 66 63 35 115 80 83 39 82 133 170
2024/20252.750 74 84 212 119 184 87 103 98 358 272 629 530
2025/20265.882 1.001 247 530 694 825 344 1.030 341 542 328 0 0
Totale 14.073